PR87282

PROVIDENCE, R.I., Dec. 16, 2020 /PRNewswire=KYODO JBN/ --

EpiVax, Inc. reports a record-breaking year for the "ISPRI" immunogenicity

screening toolkit. More pharmaceutical and biotechnology companies signed new

and continuing licenses for access to the toolkit in 2020 than ever before in

the company's twenty-two years of business.

Logo - https://mma.prnewswire.com/media/542055/EpiVax_Logo.jpg

EpiVax first developed the ISPRI toolkit in 2006 to enable drug developers to

identify and mitigate the risk of immunogenicity-related adverse events

previously associated with some biologic therapies. The toolkit incorporates a

suite of immunoinformatics tools that evaluate the potential for a given

biologic drug (such as an antibody or other protein therapy) to drive a human

immune response by predicting the T cell response to an amino acid sequence.

Unique features of the toolkit include the identification of Treg epitopes

(Tregitopes) in protein sequences and means by which users can estimate

population-level or individual-level immunogenicity risk after adjusting for

predicted Treg epitopes. Many of the applications of these tools have been

published; visit this link (https://c212.net/c/link/?t=0&l=en&o=3013699-1&h=1581282706&u=https%3A%2F%2Fwww.frontiersin.org%2Farticles%2F10.3389%2Ffimmu.2020.01301%2Ffull&a=this+link ) to read the most recent publication on immunogenicity

risk assessment by EpiVax scientists and industry experts.

Currently, the ISPRI toolkit is used by more than 100 individual drug

developers from fifteen pharmaceutical and biotechnology companies, who have

collectively screened over one million sequences over the past 12 months. This

global roster of ISPRI users includes many of the world's largest and most

cutting-edge biotechnology organizations, including Pfizer, Merck, Celgene

(BMS), Janssen (JBio), Sanofi (Aventis), Chugai (Roche), AbCellera, and more.

Five of these companies joined the ISPRI user community in 2020, highlighting

the expanding use of the toolkit and contributing to a record year of success for EpiVax.  

Reflecting on 2020 and looking forward to 2021, EpiVax commits to providing the

highest quality user experience to its existing ISPRI clients and to bringing

the decision-enabling toolkit to even more companies next year. EpiVax also

anticipates enhancing the ISPRI user experience with new tools, such as Class I

HLA epitope mapping, which is useful for cell and gene therapies.

About EpiVax:

EpiVax is a biotechnology company with expertise in T cell epitope prediction,

immune modulation, and rapid vaccine design. EpiVax's immunogenicity screening

toolkits for therapeutics and vaccines, ISPRI and iVAX, are employed in

advancing the research of a global roster of companies.  

For more information about EpiVax, visit www.epivax.com.

For more Information about ISPRI, visit this link (https://c212.net/c/link/?t=0&l=en&o=3013699-1&h=678051784&u=https%3A%2F%2Fepivax.com%2Fimmunogenicity-assessment%2Fispri-web-based-immunogenicity-screening&a=this+link ).

Press Contact:

Katie Porter, Business Development Manager

EpiVax

kporter@epivax.com

SOURCE: EpiVax, Inc.